Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Jan 14, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced that in connection with its acquisition of XOMA Corporation’s antibody manufacturing pilot plant it granted stock options and restricted
Jan 04, 2016
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced today that it has completed the previously announced acquisition of XOMA Corporation’s (NASDAQ: XOMA) antibody manufacturing pilot plant and
Dec 23, 2015
Offers the potential for rapid advancement of clinical programs and creation of new partnerships Novel class of cancer neoantigens further differentiate AutoSynVax™ vaccine platform LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative
Dec 01, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that Robert B. Stein, MD, PhD, Chief Scientific Officer and Head of R&D at Agenus will present at the Oppenheimer 26 th  Annual
Nov 12, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), today announced additional details for the Company’s upcoming R&D update session to be held on Thursday, November 19, 2015, from 4:00 to 7:00 PM Eastern Time at the: St. Regis Hotel Penthouse Two East 55 th  Street at Fifth Avenue New
Oct 27, 2015
Corporate Update Conference Call at 11 am ET Today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company discovering and developing innovative treatments for cancers and other diseases, today announced its financial results for the third quarter ended September 30,
Oct 27, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company discovering and developing innovative treatments for cancer and other diseases, announced today that GlaxoSmithKline’s plc (LSE/NYSE:GSK) second pivotal Phase III efficacy study of its shingles
Jul 23, 2015
Corporate Update Conference Call at 11 am ET Today LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company discovering and developing innovative treatments for cancers and other diseases, today announced its financial results for the second quarter ended June 30, 2015.
Jul 20, 2015
Target Expressed on Lymphocytes and Tumors Offers Unique Advantages for Unlocking the Immune Response to Fight Cancer LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that it has
Jun 22, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, June 24, 2015.
Jun 18, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that the Company will present at the 2015 JMP Securities Life Sciences Conference on Tuesday, June 23 rd  at 12:00 p.m.
Jun 17, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the appointment of C. Evan Ballantyne as the Company’s Chief Financial Officer, effective immediately. Mr.
Jun 03, 2015
Collaboration involves two proprietary Merck targets LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced today that Merck, known as MSD outside the United States and Canada, through a
Jun 01, 2015
Most significant improvements seen in patients with less elevated PD-L1 expression in peripheral blood Improvement in overall survival seen independent of MGMT methylation status LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ:AGEN), an immunology company developing innovative treatments
May 28, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that the Company will present at the Jefferies 2015 Healthcare Conference on Thursday, June 4 th  at 1:00 p.m. Eastern Time.
May 21, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing immune-oncology checkpoint modulators (CPMs), heat shock protein peptide-based vaccines and immune adjuvants, today announced that it intends to offer and sell, subject to market conditions, shares
May 21, 2015
LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $6.30 per